Abstract Search

10.22 Effect of oral insulin on prevention of diabetes in relatives of patients with T1DM: a randomized clinical trial

Writing Committee for the T1DM TrialNet Oral Insulin Study Group , JP Krischer , DA Schatz , B Bundy , JS Skyler , CJ Greenbaum

To read the full abstract: JAMA. 2017;318:1891-1902Insulin is one of the autoantigens involved in the pathogenesis of T1DM. Therefore several trials with insulin given orally, nasal or subcutaneous have been conducted to prevent the development of T1DM in genetically high risk populations. This trial design built on the results of DPT-1 and included further investigations related to first phase...

0 shares

ey0017.10-8 | (1) | ESPEYB17

10.8. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes

KC Herold , BN Bundy , SA Long , JA Bluestone , LA DiMeglio , MJ Dufort , SE Gitelman , PA Gottlieb , JP Krischer , PS Linsley , JB Marks , W Moore , A Moran , H Rodriguez , WE Russell , D Schatz , JS Skyler , E Tsalikian , DK Wherrett , AG Ziegler , CJ Greenbaum , Type 1 Diabetes TrialNet Study Group

To read the full abstract: N Engl J Med. 2019 Aug 15;381(7):603613. doi: 10.1056/NEJMoa 1902226.Type 1 diabetes (T1DM) is a chronic autoimmune disease that leads to destruction of insulin producing beta cells, which leaves the patient dependent on exogenous insulin for survival. Some interventions have delayed the loss of insulin production in T1DM, but interventions to prevent clinic...

1 shares

ESPE Yearbook of Paediatric Endocrinology

10.22 Effect of oral insulin on prevention of diabetes in relatives of patients with T1DM: a randomized clinical trial

10.8. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes

BiosciAbstracts